Latest research on Valsartan

Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Valsartan dosage

The recent PARADIGM-HF multicenter randomized controlled trial [116] tested a drug that is a combination of the ARB Valsartan and the neprilysin inhibitor sacubitril on 8399 patients with heart failure and a reduced LVEF, reporting a reduction of 20% in death from cardiovascular causes or hospitalization for heart failure as compared with the ACE inhibitor Enalapril alone at maximum dosage (p < 0.001). [source, 2016]
The doses of both CoCl2 and Valsartan were similar to those used in previous studies [16, 17]. [source, 2015]
The dose of Valsartan was similar to that used in previous studies [21]. [source, 2015]
Valsartan was administered in drinking water at the dose that did not influence systolic blood pressure (1 mg/Kg/day) [18, 19]. [source, 2015]
Rats in the Valsartan group were given Valsartan (30 mg/kg) via intragastric administration every day, and those in control and diabetic groups received the same dose of normal saline. [source, 2015]
Nevertheless, in a recent study, Giles et al. have shown that a nebivolol and Valsartan fixed-dose combination is an effective and well-tolerated treatment option for patients with hypertension [13]. [source, 2015]
Valsartan, an ARB, has dose-dependent efficacy for lowering BP. [source, 2015]
After 8 weeks of treatment, 200 and 400 mg LCZ696 reduced sitting systolic and diastolic blood pressure more than the corresponding 160 and 320 mg Valsartan doses. [source, 2015]
Valsartan is administered at a starting dose of 80 mg or 160 mg once daily and is titrated to a higher dose of 320 mg daily as required. [source, 2015]
Valsartan is primarily eliminated largely unchanged by biliary excretion in feces and renally in the urine, and exhibits dose-linear pharmacokinetics within the clinical dosing range. [source, 2015]